GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
==== Other countries ==== As of June 2008, meloxicam was registered for long-term use in cats in Australia, New Zealand, and Canada. In the United Kingdom, meloxicam is licensed for use in cats, guinea pigs, horses, and livestock including pigs and cattle.
== Research == Bifidobacterium animalis subspecies lactis BB-12 administered in combination with other probiotics has shown "a trend toward increased remission" in a study of 32 patients with ulcerative colitis. Research on Bifidobacterium animalis supplementation in preterm infants, as detailed in the systematic review by Szajewska et al., a meta-analysis of four randomized controlled trials (RCTs) involving a total of 324 infants, has shown promising results. These include increased fecal bifidobacteria counts, reduced Enterobacteriaceae and Clostridium spp counts, as well as improvements in stool pH, fecal calprotectin concentrations, fecal immunoglobulin A levels, and short-chain fatty acid concentrations. However, the analysis did not find significant effects on the risk of necrotizing enterocolitis stage ≥2, risk of sepsis, or use of antibiotics compared to controls.
where χi denotes the mole fraction of component i. For greater accuracy, the critical point can be calculated using equations of state, such as the Peng–Robinson, or group-contribution methods. Other properties, such as density, can also be calculated using equations of state.
Some research has been carried out to improve the efficacy of commercial incandescent lamps. In 2007, General Electric announced a high efficiency incandescent (HEI) lamp project, which they claimed would ultimately be as much as four times more efficient than current incandescents, although their initial production goal was to be approximately twice as efficient. The HEI program was terminated in 2008 due to slow progress. US Department of Energy research at Sandia National Laboratories initially indicated the potential for dramatically improved efficiency from a photonic lattice filament. However, later work indicated that initially promising results were in error. Prompted by legislation in various countries mandating increased bulb efficiency, hybrid incandescent bulbs have been introduced by Philips. The Halogena Energy Saver incandescents can produce about 23 lm/W; about 30 percent more efficient than traditional incandescents, by using a reflective capsule to reflect formerly wasted infrared radiation back to the filament, from which some is re-emitted as visible light. This concept was pioneered by Duro-Test in 1980 with a commercial product that produced 29.8 lm/W. More advanced reflectors based on interference filters or photonic crystals can theoretically result in higher efficiency, up to a limit of about 270 lm/W (40% of the maximum efficacy possible). Laboratory proof-of-concept experiments have produced as much as 45 lm/W, approaching the efficacy of compact fluorescent bulbs which is still lower than LED bulbs.
== tRNA/synthetase pair == Another key element is the tRNA/synthetase pair. The orthologous set of synthetase and tRNA can be mutated and screened through directed evolution to charge the tRNA with a different, even novel, amino acid. Mutations to the plasmid containing the pair can be introduced by error-prone PCR or through degenerate primers for the synthetase's active site. Selection involves multiple rounds of a two-step process, where the plasmid is transferred into cells expressing chloramphenicol acetyl transferase with a premature amber codon. In the presence of toxic chloramphenicol and the non-natural amino acid, the surviving cells will have overridden the amber codon using the orthogonal tRNA aminoacylated with either the standard amino acids or the non-natural one. To remove the former, the plasmid is inserted into cells with a barnase gene (toxic) with a premature amber codon but without the non-natural amino acid, removing all the orthogonal syntheses that do not specifically recognize the non-natural amino acid. In addition to the recoding of the tRNA to a different codon, they can be mutated to recognize a four-base codon, allowing additional free coding options. The non-natural amino acid, as a result, introduces diverse physicochemical and biological properties in order to be used as a tool to explore protein structure and function or to create novel or enhanced protein for practical purposes.
Sources: en.wikipedia.org
The second largest European contingent was from France, which committed 18,000 troops. Operating on the left flank of the US XVIII Airborne Corps, the French Army force was the Division Daguet, including troops from the French Foreign Legion. Initially, the French operated independently under national command and control, but coordinated closely with the Americans (via CENTCOM) and Saudis. In January, the Division was placed under the tactical control of the XVIII Airborne Corps. France also deployed several combat aircraft and naval units. The French called their contribution Opération Daguet.
=== Biosynthesis === Similar to other pheromone biosynthesis reactions, female cabbage looper pheromone production initiates with synthesis of 16 and 18-carbon fatty acids. This is followed by desaturation at C1 and chain shortening by two or four carbons. Finally, the fatty acid is reduced and acetylated to form an acetate ester. The result is a blend of different female pheromone compounds at a consistent ratio. This ratio can be highly altered by mutations in chain shortening proteins, demonstrating that the chain shortening step is important for determining the ratio of pheromones in the final blend. As a species, the cabbage looper does not hormonally regulate pheromone production. Stage specific proteins correspond to the development of the pheromone gland. The immature gland lacks numerous enzymes crucial to pheromone biosynthesis, such as fatty acid synthetase and acetyltransferase, which is why the looper cannot produce pheromones prior to the adult stage. Upon complete development of the pheromone glands at the adult stage, pheromones are constantly produced.
=== Trump's victory === Although many conventional metrics indicated that the American economy had recovered from the COVID-19 pandemic (wages increased and inflation was in check), and although migrant crossings at the U.S.-Mexico border had declined significantly since earlier in the Biden administration, an AP article stated that Trump was able to convince voters to support him in 2024 by promising to fix the economy and block the flow of immigrants at the border. According to exit polls, voters whose top issues were the economy and immigration largely voted for Trump. Time's Eric Cortellessa wrote that the thesis of Trump's campaign boiled down to this simple slogan: "Max out the men and hold the women". To accomplish this goal, Trump "relentlessly" emphasized the economy and immigration. Cortellessa also mentioned Trump's minimization of his numerous controversies and his success in having his criminal trials postponed until after the election. He said that Trump's "advanced age and increasingly incoherent trail rhetoric" were taken in stride by voters, and that "much of the country read Trump's legal woes as part of a larger corrupt conspiracy to deny him, and them, power". NPR wrote that "Americans have continued to chafe at higher than pre-pandemic prices and the lack of affordable housing", and that much of the voter placed the blame "squarely" on the Biden administration. NPR said demographics played an important role in the election, with White voters going up as a share of the electorate from 67% to 71% and Trump winning 46% of Latinos.
Likewise, according to this second interpretation, a living body is alive not only because of its structure but also because of an additional property: the soul, which a properly organized body needs in order to be alive. John Vella uses Frankenstein's monster to illustrate the second interpretation: the corpse lying on Frankenstein's table is already a fully organized human body, but it is not yet alive; when Frankenstein activates his machine, the corpse gains a new property, the property of life, which Aristotle would call the soul.
N-Acetylcysteine ethyl ester (NACET, NAC-Et) is an antioxidant which acts as a lipophilic prodrug for N-acetylcysteine and subsequently glutathione, with improved bioavailability over N-acetylcysteine itself, and has been researched in animal studies as a potential treatment for diabetic retinopathy. It has also been sold as a "dietary supplement" in combination with glycine under the name GlyNAC-Et as a supposedly improved version of the older glycine-NAC combination GlyNAC which has been claimed to show efficacy in counteracting symptoms associated with aging as well as HIV infection, diabetes and nerve damage. Several related compounds such as γ-glutamylcysteine ethyl ester and glutathione ethyl ester have been investigated for similar applications.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。